3'-[(1S,3S)-3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentylsulfamoyl]-biphenyl-4-carboxylic acid amide | 1034174-76-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3'-[(1S,3S)-3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentylsulfamoyl]-biphenyl-4-carboxylic acid amide
• 英文别名: 4-[3-[[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)cyclopentyl]sulfamoyl]phenyl]benzamide
• CAS: 1034174-76-9
• 化学式: C₂₂H₂₂FN₅O₄S
• 分子量: 471.512
• InChiKey: NCDSPSIXGBHJMZ-IRXDYDNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  156
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-4-bromo-benzenesulfonamide 、 4-氨基甲酰苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 生成 3'-[(1S,3S)-3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentylsulfamoyl]-biphenyl-4-carboxylic acid amide
  参考文献：
  名称：

  Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors

  摘要：

  A series of deoxycytidine kinase inhibitors was simultaneously optimized for potency and PK properties. A co-crystal structure then allowed merging this series with a high throughput screening hit to afford a highly potent, selective and orally bioavailable inhibitor, compound 10. This compound showed dose dependent inhibition of deoxycytidine kinase in vivo. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.081

文献信息

• Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
  作者：Theodore C. Jessop、James E. Tarver、Marianne Carlsen、Amy Xu、Jason P. Healy、Alexander Heim-Riether、Qinghong Fu、Jerry A. Taylor、David J. Augeri、Min Shen、Terry R. Stouch、Ronald V. Swanson、Leslie W. Tari、Michael Hunter、Isaac Hoffman、Philip E. Keyes、Xuan-Chuan Yu、Maricar Miranda、Qingyun Liu、Jonathan C. Swaffield、S. David Kimball、Amr Nouraldeen、Alan G.E. Wilson、Ann Marie DiGeorge Foushee、Kanchan Jhaver、Rick Finch、Steve Anderson、Tamas Oravecz、Kenneth G. Carson

  DOI：10.1016/j.bmcl.2009.09.081

  日期：2009.12

  A series of deoxycytidine kinase inhibitors was simultaneously optimized for potency and PK properties. A co-crystal structure then allowed merging this series with a high throughput screening hit to afford a highly potent, selective and orally bioavailable inhibitor, compound 10. This compound showed dose dependent inhibition of deoxycytidine kinase in vivo. (C) 2009 Elsevier Ltd. All rights reserved.